Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascular events (MACE) compared to placebo. Although the drug effectively reduced inflammation markers, it did not lower risks of cardiovascular death, heart attack, or stroke. Safety profiles were similar between ziltivekimab and placebo, with a higher rate of serious infections in the treatment group. Novo Nordisk will continue two other cardiovascular trials with ziltivekimab and does not expect the ZEUS outcome to affect its 2026 profit outlook, despite a planned non-cash impairment charge.
Shares of Novo Nordisk fell sharply after the company announced that its late-stage trial for the heart drug ziltivekimab did not significantly reduce major cardiovascular events like heart attack, stroke, or cardiovascular death compared to a placeb...
Novo Resources is set to start a 2,700-metre drilling program at its Tibooburra Gold Project in New South Wales in late September 2026, pending approvals. Pantoro Gold reported solid gold production and cost efficiency at its Norseman mine, with grow...
Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone...
A U.S. judge has allowed parts of a shareholder lawsuit against Novo Nordisk to move forward, alleging the company misled investors about the design and tolerability of its experimental weight-loss drug CagriSema. Investors claim Novo did not fully d...
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
